Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease

NCT02769494 is registered in ClinicalTrials.gov with Xijing Hospital of Digestive Diseases as lead sponsor.

NCT NCT02769494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02769494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease
Lead sponsor
Xijing Hospital of Digestive Diseases
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
January 31, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, oral ulcer